- Home
- TSHA vs RFMZ Comparison
TSHA vs RFMZ Comparison
Compare TSHA & RFMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- RFMZ
- Stock Information
- Founded
- TSHA 2019
- RFMZ 2021
- Country
- TSHA United States
- RFMZ United States
- Employees
- TSHA N/A
- RFMZ N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- RFMZ Trusts Except Educational Religious and Charitable
- Sector
- TSHA Health Care
- RFMZ Finance
- Exchange
- TSHA Nasdaq
- RFMZ Nasdaq
- Market Cap
- TSHA 334.1M
- RFMZ 346.8M
- IPO Year
- TSHA 2020
- RFMZ N/A
- Fundamental
- Price
- TSHA $1.61
- RFMZ $14.24
- Analyst Decision
- TSHA Strong Buy
- RFMZ
- Analyst Count
- TSHA 8
- RFMZ 0
- Target Price
- TSHA $6.63
- RFMZ N/A
- AVG Volume (30 Days)
- TSHA 2.1M
- RFMZ 76.6K
- Earning Date
- TSHA 02-26-2025
- RFMZ 01-01-0001
- Dividend Yield
- TSHA N/A
- RFMZ 7.43%
- EPS Growth
- TSHA N/A
- RFMZ N/A
- EPS
- TSHA N/A
- RFMZ 0.65
- Revenue
- TSHA $9,915,000.00
- RFMZ N/A
- Revenue This Year
- TSHA N/A
- RFMZ N/A
- Revenue Next Year
- TSHA N/A
- RFMZ N/A
- P/E Ratio
- TSHA N/A
- RFMZ $21.49
- Revenue Growth
- TSHA N/A
- RFMZ N/A
- 52 Week Low
- TSHA $1.19
- RFMZ $11.28
- 52 Week High
- TSHA $4.32
- RFMZ $14.57
- Technical
- Relative Strength Index (RSI)
- TSHA 46.14
- RFMZ 57.21
- Support Level
- TSHA $1.46
- RFMZ $13.97
- Resistance Level
- TSHA $1.76
- RFMZ $14.39
- Average True Range (ATR)
- TSHA 0.15
- RFMZ 0.17
- MACD
- TSHA 0.01
- RFMZ -0.01
- Stochastic Oscillator
- TSHA 39.33
- RFMZ 42.00
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About RFMZ RiverNorth Flexible Municipal Income Fund II Inc.
RiverNorth Flex Muni Income Fund II Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.